Delivery Order SPE2DB24D1021-SPE2DB25FEXJX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,193.52 to AmerisourceBergen Drug Corp on June 3, 2025, for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitive award, with no set-aside designation, was issued under firm fixed pricing and is scheduled for completion by June 4, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order is supported by...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $5,179.06 for OmniPod 5 Dexcom G7 generation 5 insulin delivery pods. This is a firm fixed price, non-set-aside contract with a completion date of September 25, 2025. The work will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $6,285.41 firm fixed price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods on September 2, 2025. This is a non-set-aside competitive award with an ultimate completion date of September 3, 2025, and performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,549.48 to AmerisourceBergen Drug Corp for Omnipod 5 Dexcom G7 Generation 5 insulin delivery systems. Issued on July 23, 2025, with a completion date of July 24, 2025, this firm fixed-price delivery order represents a competitive award with no set-aside designation. The award is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $2,395.34 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed price procurement with no set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this medical device delivery, which supports the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $9,190.25 to AmerisourceBergen Drug Corp on September 4, 2025, for OmniPod 5 Dexcom G7 insulin delivery pods (Generation 5), with a completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical and medical device supplier to the federal government. The delivery will be fulfilled from the vendor's corporate office in...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for OmniPod 5 Dexcom G7 generation 5 insulin infusion pump pods. This $32,078.67 firm fixed-price delivery order, which is a child contract under a larger indefinite delivery vehicle, represents a competitive award with no set-aside designation. The products will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of...
- The Defense Logistics Agency awarded a $11,008.89 firm fixed-price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. The award was issued on August 28, 2025, with an ultimate completion date of August 29, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods, valued at $2,164.28. This non-competitive delivery order represents a firm fixed-price contract with an ultimate completion date of April 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,531.79 to AmerisourceBergen Drug Corp for OmniPod 5 with Dexcom G7 continuous glucose monitoring system (Generation 5) on June 4, 2025, with completion expected by June 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEXJXDelivery Order
The Defense Logistics Agency awarded a $1,790.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Omnipod 5 Dexcom G7 Generation 5 insulin infusion pods on June 4, 2025. This is a non-set-aside competitive award with an ultimate completion date of June 5, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through the Defense Logistics Agency's Medical Supply Chain. The company's extensive portfolio of federal contract awards demonstrates its capability to fulfill diverse medical supply requirements, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order for continuous glucose monitoring and insulin delivery devices supports the healthcare needs of the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems as part of DLA's comprehensive pharmaceutical prime vendor program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 6/4/25 |